Answers are grounded in this paper and cite their sources.
Investigates HDAC inhibition in leukemia and prostate cancer cells, suggesting potential therapeutic avenues.
cell proliferation, enhanced histone and tubulin acetylation, upregulated p21, and downregulated Bcl-2. These findings identify biphenyl-substituted UBHAs as promising therapeutics and probes to dissect HDAC biology.
No takes yet. Share an insight, caveat, or question.
Fiorentino et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: